|Bid||9.25 x 4000|
|Ask||9.60 x 1400|
|Day's Range||8.90 - 9.45|
|52 Week Range||4.61 - 55.47|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 05, 2022 - Oct 10, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.69|
Good day, and thank you for standing by, and welcome to the Accolade first quarter 2023 earnings results conference call. With me on the call today are our chief executive officer, Rajeev Singh; and our chief financial officer, Steve Barnes. Shantanu Nundy, our chief medical officer, will join for the question-and-answer portion of the call.
Accolade (ACCD) delivered earnings and revenue surprises of 45.21% and 3.80%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Fiscal first quarter 2023 revenue of $85.5 million, a 44% increase compared to fiscal first quarter 2022 revenue of $59.5 million SEATTLE, June 30, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2022. “The healthcare consumer has never been more in need of true Personalized Healthcare. Two years into the Covid-19 pandemic, the healthcare system remains as complex and difficult to navigate as ever. Our customers,